The Malaysian government will intensify support for domestic drug production to reduce healthcare costs and improve access to medicines for its citizens.
A report by BMI, a market research firm under Fitch Solutions, indicates that the focus of this policy is to increase the share of domestically produced medical products and establish a legal framework that prioritizes essential medicines, especially generic drugs and biosimilars.
The Malaysian Ministry of Health will introduce a significant shift in its procurement policy, prioritizing suppliers with investments in local production, while also strengthening its capacity to negotiate prices and making affordable generic drugs the default prescription option when available.
People walk outside the Petronas Towers in Kuala Lumpur, Malaysia. Photo by Reuters |
This strategy of prioritizing generic medicines has yielded significant economic benefits, saving the Malaysian government more than US$220 million over the past two years as of January 2026. It is also identified as a core objective in the 13th Malaysia Plan for 2026-2030 and the Health White Paper, aiming to reshape prescribing habits among physicians and strengthen public confidence in lower-cost, equivalent treatments.
Under Budget 2026, total public healthcare expenditure is set at 419 billion MYR ($106.7 billion), marking the first overall contraction since 2020. However, the Ministry of Health will still receive 46.5 billion MYR, up from 45.3 billion MYR in 2025.
The strong promotion of domestically produced medicines is expected to create significant competitive pressure on pharmaceutical manufacturers seeking to expand their presence in this Southeast Asian nation.
Comments are closed.